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Thousands of people suffer from severe malaria every year. The innate immune response plays a determinant role in host’s defence
to malaria. Transient receptor potential vanilloid 1 (TRPV1) modulates macrophage-mediated responses in sepsis, but its role in
other pathogenic diseases has never been addressed. We investigated the effects of capsazepine, a TRPV1 antagonist, in malaria.
C57BL/6 mice received 105 red blood cells infected with Plasmodium bergheiANKA intraperitoneally. Noninfected mice were used
as controls. Capsazepine or vehicle was given intraperitoneally for 6 days. Mice were culled on day 7 after infection and blood and
spleen cell phenotype and activation were evaluated. Capsazepine decreased circulating but not spleen F4/80+Ly6G+ cell numbers
as well as activation of both F4/80+and F4/80+Ly6G+ cells in infected animals. In addition, capsazepine increased circulating but
not spleen GR1+ and natural killer (NK) population, without interfering with natural killer T (NKT) cell numbers and blood NK
and NKT activation. However, capsazepine diminished CD69 expression in spleen NKT but not NK cells. Infection increased lipid
peroxidation and the release of TNF𝛼 and IFN𝛾, although capsazepine-treated group exhibited lower levels of lipid peroxidation
and TNF𝛼. Capsazepine treatment did not affect parasitaemia. Overall, TRPV1 antagonismmodulates the innate immune response
to malaria.
1. Introduction
Malaria is an infectious disease caused by intracellular
protozoans of the genus Plasmodium and transmitted from
person to person through bites of infected mosquitoes. It
affects millions of people annually and is a leading cause of
child mortality in underdevelopment countries [1]. Severe
malaria such as cerebral malaria is frequently fatal and
outcome of infection depends on host’s immune response,
with innate immunity playing a determinant role in it [2,
3]. Available antimalarial therapy targets the Plasmodium.
However, elimination of the parasite does not halt the clinical
consequences of disease as surviving patients from severe
malaria can develop a range of neurological deficits [4, 5].
In this context, an effective immune response is essential for
patient’s recovery. Innate response is the major immunity
component of patients who have been infected with Plasmod-
ium for the first time, being essential to the development of an
effective acquired immune response [6].
Recently, a protective role for transient receptor vanilloid
1 (TRPV1), a nonselective cation channel found on both
neuronal and nonneuronal cells, was suggested in bacteria-
induced sepsis [7–10]. Indeed, in the absence of TRPV1
activation, macrophage functions such as their ability to
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phagocytose and to release inflammatory mediators (nitric
oxide (NO), reactive oxygen species (ROS), and cytokines)
are impaired [9]. Also, TRPV1 has been linked tomacrophage
survival [9]. Evidence suggests a feedback between TRPV1
activation and ROS production may exist; in addition to
modulating oxidative stress by downregulating ROS gener-
ation, this receptor can be directly activated by hydrogen
peroxide (H
2
O
2
) [11] and regulated by superoxide anion
(O
2
−
) release [12–14]. Oxidative stress generation has a direct
impact on macrophage-erythrocyte-endothelium interac-
tions and imbalances of this pathway may trigger excessive
damage and impaired host’s immune response to malaria
[15, 16].
Herein, the role of TRPV1 in malaria was investigated for
the first time.We used the TRPV1 antagonist, capsazepine, to
assess whether TRPV1 is able tomodulate the innate immune
response to malaria in animals infected with Plasmodium
berghei ANKA.
2. Materials and Methods
2.1. Animals. Inbred male C57BL/6 mice (8 weeks old) were
used. Mice were obtained from the animal’s facility of the
Department of Parasitology, Institute of Biomedical Sciences,
University of Sa˜o Paulo. Mice were kept in a climatically
controlled environment and given food and water ad libitum.
All procedures were approved by the Ethics Committee of the
University of Sa˜o Paulo and carried out in accordance with
the Brazilian society for animal welfare (SBCAL).
2.2. Malaria Induction. Malaria was induced by a single
intraperitoneal (i.p.) injection of 105 red blood cells (RBCs)
infected with Plasmodium berghei ANKA (clone 1.49L) as
described by Elias et al. [17]. Parasitaemia was assessed daily
in a blood smear stained by Giemsa, by microscopy, from
day 5 to day 7 following infection and was expressed as %
of infected RBCs. Mice were terminally anaesthetised with
a mixture of ketamine (75mg/kg; Dopalen, Ceva, Brazil)
and xylazine (1mg/kg; i.p.; Sigma-Aldrich, Brazil), and
exsanguinated by cardiac puncture on day 7 after infection
(premortality end point; [18, 19]).Their blood and spleenwere
collected for further analysis. The plasma was separated and
stored at −70∘C for further quantitation of plasma aldehydes
and cytokines. Cell population phenotype and activation
were evaluated by flow cytometry. Noninfected mice were
used as controls.
2.3. Pharmacological Treatment. In order to assess the role of
TRPV1 in malaria, animals received the TRPV1 antagonist,
capsazepine (Sigma-Aldrich, Brazil; 𝑛 = 5, uninfected (con-
trol) group and 𝑛 = 8, infected group), intraperitoneally from
24 h following infection, for 6 days (2x day, 50 𝜇g/animal;
[9]). Vehicle (10% DMSO in saline, 120 𝜇L/animal; 𝑛 = 5,
uninfected (control) group and 𝑛 = 8, infected group) was
used as controls.
2.4. Flow Cytometry Analysis. Blood and spleen samples
from infected and uninfected mice and single-cell suspen-
sions were prepared. Peripheral blood cells were isolated
by Percoll gradient (Sigma-Aldrich, Brazil). Spleens were
homogenized and passed through a nylon mesh of 70 𝜇m
to create a single-cell suspension. Cells were stained with
Trypan blue (Sigma-Aldrich, Brazil) and assessed for viability
in a haemocytometer. Cells (106) were washed, resuspended
in flow cytometry buffer (2% foetal calf serum (Invitrogen,
Brazil) in phosphate buffered saline-PBS (Sigma-Aldrich,
Brazil)), and stained with directly conjugated monoclonal
antibodies (BD Biosciences or eBiosciences, Brazil): anti-
F4/80 FITC, anti-IAb PE, anti-Ly6G PerCP, anti-GR1 Pe-
Cy7, anti-CD3 PE and APC, anti-NK1.1 FITC, and anti-
CD69 PECy5. Events were acquired on a BD FACSCanto
(BD Biosciences-Immunocytometry Systems) and analyzed
using FlowJo software (Tree Star Inc.). In order to ana-
lyzemonocyte/macrophage and neutrophil populations, cells
expressing CD3+, CD4+, CD8+, and CD19+ were gated out
and the phenotypic F4/80, GR1, and Ly6G lineage markers
were evaluated. Results are expressed as representative two-
colour dot-plots as well as number of cells (×106), except for
IAb, expressed as mean fluorescence.
2.5. Plasma Cytokine Levels. The plasma levels of TNF𝛼,
IFN𝛾, IL-4, IL-6, IL-2, IL-10, and IL-17 were evaluated by
using a cytometric bead array (CBA) mouse Th1/Th2/Th17
cytokine kit (BD Biosciences, Brazil) according to man-
ufacturer’s instructions. Analysis was performed on a
Facscalibur cytometer flow cytometer (BD Biosciences-
Immunocytometry Systems). Results were calculated in CBA
FCAP Array software (BD Biosciences, Brazil) as pg/mL and
are expressed as fold-increase relative to uninfected controls.
2.6. Plasma Aldehydes. Total plasma aldehyde (mainly mal-
ondialdehyde) concentrations were quantified as an index
of lipid peroxidation and oxidative stress, as previously
described [20, 21]. Briefly, 100 𝜇L of sample were incubated
with 100 𝜇L of PBS and 400 𝜇L of thiobarbituric acid (0.67%;
Sigma-Aldrich, Brazil), at 90∘C for 45min. Samples were then
centrifuged at 1,000 xg for 10min. Three hundred 𝜇L of the
supernatant was incubated with 300 𝜇L of butanol (Sigma-
Aldrich, Brazil) and 30 𝜇L of a saturated solution of sodium
chloride (Sigma-Aldrich, Brazil). Samples were mixed in a
vortex, centrifuged at 1,000 xg for 2min and then added
to a 96-well plate (200𝜇L/well). Absorbance was read at
535 and 572 nm and the difference between the absorbance
was used to calculate the aldehyde concentrations, using
the molar extinction coefficient of the chromophore (1.56 ×
105M−1/cm−1). Results are expressed as fold-increase relative
to uninfected controls.
2.7. Data Analysis. The results are presented as the mean ±
standard deviation (SD). The percentages of inhibition are
reported as mean ± SD of inhibitions obtained in each indi-
vidual experiment compared with control samples. Statistical
comparisons of the datawere performed byANOVA followed
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by Bonferroni and unpaired 𝑡-test when appropriate. The 𝑃
values < 0.05 were considered significant.
3. Results
3.1. CapsazepineDoesNotAffect Parasitaemia. Figure 1 shows
parasitaemia levels up to day 7 after infection, in mice treated
with either vehicle or capsazepine. Parasitaemia progres-
sively increased in both groups. Repeated treatment with
capsazepine had no effect on parasitaemia. Experiments were
performed with a premortality end-point. Thus, no signs of
cerebral malaria such as reduced responsiveness to stimula-
tion, ataxia, respiratory distress or prostration, paralysis, and
convulsions were observed in either capsazepine- or vehicle-
infected mice. However, both groups of animals displayed
piloerection and/or abnormal posture, as a result of infection.
3.2. Capsazepine Alters Circulating Monocyte but Not Spleen
Macrophage Population Number and Activation. As repre-
sented in Figures 2(a)–2(e), three distinct populations of
peripheral blood leukocytes were detected in all groups of
uninfected and infected animals: F4/80+, F4/80+Ly6G+ and
Ly6G+ cells. Malaria induction had no effect on Ly6G+
cell population as no statistical significance was found
between any of the evaluated groups. Mean ± SD values for
Ly6G+ populations are as follows: vehicle-uninfected group
2.0 ± 0.6, capsazepine uninfected group 1.3 ± 0.4, vehicle-
infected group 0.9 ± 1.1, and capsazepine infected group
1.3 ± 0.8. On the other hand, P. berghei ANKA infection
increased F4/80+Ly6G+ cell numbers in both vehicle- (3.9-
fold increase) and capsazepine- (1.9-fold increase) treated
groups when compared to uninfected controls, whilst no
effects were observed on F4/80+ cell population (Figures 2(b)
and 2(c)). In addition, malaria caused increased activation
of both F4/80+ (5.1-fold increase) and F4/80+Ly6G+ (6.6-
fold increase) circulating cells when compared to uninfected
animals, as denoted by expression of IAb on these cells (Fig-
ures 2(d) and 2(e)). Repeated administration of capsazepine
in infected animals caused reduction of F4/80+Ly6G+ pop-
ulation expansion by 25.0 ± 5.2% but did not affect F4/80+
cell numbers (Figures 2(b) and 2(c)). In addition, P. berghei
ANKA-induced activation of F4/80+ and F4/80+Ly6G+ cells
was halted by capsazepine. As depicted in Figures 2(d)
and 2(e), capsazepine treatment reduced by 75 ± 22.7%
and 90.3 ± 7.1%, the expression of IAb on F4/80+ and
F4/80+Ly6G+ cells, respectively, when compared to vehicle-
treated infected controls. As infection raised the number
of circulating F4/80+Ly6G+ cells, a decline was noticed in
the GR1+ cell population (34.1 ± 15.1%). However, infected
mice treated with capsazepine exhibited a higher number
of these cells when compared with both their uninfected-
(1.8-fold increase) and infected- (2.4-fold increase) control
animals. Mean ± SD values for GR1+ populations are as
follows: vehicle-uninfected group 2.9 ± 0.6, capsazepine
uninfected group 2.5 ± 0.4, vehicle-infected group 1.9 ±
0.4, and capsazepine infected group 4.6 ± 0.5 (𝑃 < 0.05).
Capsazepine treatment in uninfected animals had no effects
in regard to expansion or activation of both F4/80+ and
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Figure 1: Effect of capsazepine on parasitaemia levels. Parasitaemia
was measured daily, from day 5 to day 7 after infection in blood
smear samples obtained fromC57BL/6mice infected with Plasmod-
ium berghei ANKA (105 infected RBCs/animal; i.p.) treated with
either capsazepine (50𝜇g/animal, 2x day, for 6 days) or vehicle (10%
DMSO in saline) from 24 h after infection (𝑛 = 8 per group).
F4/80+Ly6G+ cells (Figures 2(a)–2(e)) and neither on GR1+
cells.
Similarly, F4/80+, F4/80+Ly6G+ and Ly6G+ cells were
detected in spleen samples obtained from both infected
and uninfected mice whether or not they were treated with
capsazepine (Figures 3(a)–3(e)). As observed for circulating
Ly6G+ cells, malaria induction had no effects on spleen
Ly6G+ cells. Mean ± SD values for spleen Ly6G+ populations
are as follows: vehicle-uninfected group 0.7±0.2, capsazepine
uninfected group 1.1 ± 0.4, vehicle-infected group 1.0 ±
0.6, and capsazepine infected group 0.9 ± 0.3. However,
P. berghei ANKA injection raised the numbers of F4/80+
and F4/80+Ly6G+ cells in both vehicle- (2.0- and 5.8-fold
increase, resp.) and capsazepine- (1.5- and 4.9-fold increase,
resp.) treated groups when compared to their respective
uninfected controls (Figures 3(b) and 3(c)). Also, P. berghei
ANKA infection augmented F4/80+ and F4/80+Ly6G+ cells
in both vehicle- (5.5- and 2.0-fold increase, resp.) and
capsazepine- (2.3- and 1.8-fold increase, resp.) treated groups
when compared to their respective uninfected controls (Fig-
ures 3(d) and 3(e)). Capsazepine had no effects on the
number or activation of spleen F4/80+ and F4/80+Ly6G+ cells
(Figures 3(a)–3(e)). Spleen GR1+ cell population remained
unaltered irrespective of treatments and mean ± SD values
are as follows: vehicle-uninfected group 0.9±0.2, capsazepine
uninfected group 1.3 ± 0.6, vehicle-infected group 0.8 ±
0.3, and capsazepine infected group 1.3 ± 0.4. Moreover,
capsazepine had no effects on F4/80+ and F4/80+Ly6G+ cells
(Figures 3(a)–3(e)) when administered to uninfected mice.
3.3. Capsazepine Modulates Blood and Spleen NK and
NKT Population Number and Activation. We also evaluated
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Figure 2: Effect of capsazepine on peripheral blood F4/80+, F4/80+Ly6G+, and Ly6G+ cells. (a) Representative two-colour dot-plots for
peripheral blood F4/80+, F4/80+Ly6G+, and Ly6G+ cell populations from uninfected and Plasmodium berghei ANKA-infected mice (105
infected RBCs/animal; i.p.). Circulating (b) F4/80+ and (c) F4/80+Ly6G+ cell numbers in uninfected and Plasmodium bergheiANKA-infected
mice (105 infected RBCs/animal; i.p.). Expression of IAb (mean fluorescence) on circulating (d) F4/80+ and (e) F4/80+Ly6G+ cell populations.
Capsazepine (50𝜇g/animal, 2x day, for 6 days) was administered from 24 h infection. Vehicle- (10% DMSO in saline) treated animals were
used as controls. Data are expressed as mean ± SD, 𝑛 = 5 per group. ∗𝑃 < 0.05 compared with respective uninfected (control) groups;
#
𝑃 < 0.05 compared with vehicle-treated infected group.
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Figure 3: Effect of capsazepine on spleen F4/80+, F4/80+Ly6G+, and Ly6G+ cells. (a) Representative two-colour dot-plots for spleen F4/80+,
F4/80+Ly6G+, and Ly6G+ cell populations from uninfected and Plasmodium berghei ANKA-infected mice (105 infected RBCs/animal; i.p.).
Spleen (b) F4/80+ and (c) F4/80+Ly6G+ cell numbers in uninfected and Plasmodium bergheiANKA-infectedmice (105 infected RBCs/animal;
i.p.). Expression of IAb (mean fluorescence) on spleen (d) F4/80+ and (e) F4/80+Ly6G+ cell populations. Capsazepine (50𝜇g/animal, 2x day,
for 6 days)was administered from24 h after infection.Vehicle- (10%DMSO in saline) treated animalswere used as controls.Data are expressed
as mean ± SD, 𝑛 = 5 per group. ∗𝑃 < 0.05 compared with respective uninfected (control) groups.
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the effects of capsazepine on circulating and spleen NK
(CD3−NK1.1+) and NKT (CD3+NK1.1+) cells. Peripheral
blood NK and NKT cells were detected in all groups of
uninfected and infected animals (Figures 4(a)–4(e)). Malaria
induction had no effects on either NK or NKT cell numbers
when compared to uninfected control mice (Figures 4(b) and
4(d)). On the other hand, NK, but not NKT activation via
CD69 expression, was increased in both vehicle- (11.1-fold
increase) and capsazepine- (11.5-fold increase) treated groups
when compared to their respective uninfected controls
(Figure 4(c)). However, capsazepine treatment significantly
increased NK cell population (Figure 4(b)) when compared
to either its uninfected control group (1.8-fold increase)
or vehicle-treated infected animals (1.5-fold increase). Also,
capsazepine was able to enhance activation of NKT-infected
cells (2.7-fold increase; Figure 4(e)). Importantly, NK cells
account for the majority of circulating and activated NK1.1+
cells in infected animals (Figure 4).
Similarly, spleen NK and NKT cells were detected in all
groups of uninfected and infected animals (Figures 5(a)–
5(e)). Malaria induction caused spleen NKT but not NK
cell population expansion when compared to uninfected
control mice (Figures 5(b) and 5(d)). This was observed
for both vehicle- (5.6-fold increase) and capsazepine- (4.1-
fold increase) treated mice (Figure 5(d)). Figures 5(c) and
5(e) demonstrate that CD69 expression was augmented on
both spleen NK and NKT cells obtained from infected mice
treatedwith either vehicle (5.3- and 6.9-fold increase, resp.) or
capsazepine (5.6- and 3.1-fold increase, resp.). However, NKT
activationwas 45.7±17.5% lower in capsazepine-treatedmice
when compared to vehicle-infected controls (Figure 5(e)).
Capsazepine treatment in infected mice had no effects on
spleenNKandNKTcell numbers orNKactivation (Figure 5).
Similarly, capsazepine did not alter spleen NK and NKT
profile (cell number and activation) in samples obtained from
uninfected mice (Figure 5).
3.4. Capsazepine Reduces Lipid Peroxidation and Plasma
TNF𝛼 Levels in P. berghei ANKA-Infected Mice. P. berghei
ANKA infection increased lipid peroxidation in both vehicle-
and capsazepine-treated mice, as demonstrated by the levels
of plasma aldehydes (Figure 6(a)). However, this increase was
less pronounced in the capsazepine-treated group (20.5±6.4%
reduction). Malaria also triggered the release of TNF𝛼 and
IFN𝛾 in both infected groups (Figures 6(b) and 6(c)). TNF𝛼
production was markedly reduced by capsazepine treatment
(70.8 ± 14.5%; Figure 6(b)). On the other hand, capsazepine
treatment did not affect IFN𝛾 release triggered by malaria
(Figure 6(c)). Vehicle- and capsazepine-treated uninfected
mice exhibited similar levels of plasma aldehydes, TNF𝛼, and
IFN𝛾 (data not shown). Production of IL-4, IL-6, IL-2, IL-10,
and IL-17 was not detected in any of the evaluated groups.
4. Discussion
Since its discovery, evidence has accumulated that TRPV1
has the potential to play a key role in a variety of patholo-
gies, especially those associated with imbalances of the
immune and inflammatory response, such as asthma [22–
24] and rheumatoid arthritis [25–27]. Recent reports demon-
strated that TRPV1 is expressed on immune cells such as
macrophages and peripheral-blood mononuclear cells in
inflammatory conditions [9, 28–30]. More recently, TRPV1
was suggested to modulate a range of macrophage-mediated
responses to bacterial infection [9]. Indeed, TRPV1 deletion
or antagonism has been associated with poorer outcome of
experimental sepsis as TRPV1 blockade increases pathogen
load and also facilitates the transition from a local to a
systemic inflammatory response to bacteria [7, 9, 10, 31–34].
In addition, TRPV1 knockout (TRPV1 KO) mice challenged
with intestinal bacteria or LPS present with a dysregulated
production of inflammatory mediators, including NO, ROS,
and cytokines such as TNF𝛼, IL-10, and IL-6 [7–9]. So far,
there are no reports of TRPV1 playing any roles in the
immune response to other pathogens.
Here, we show for the first time that TRPV1 antagonism
by capsazepine, a nonselective antagonist, modulates the
innate immune response tomalaria. Reports have shown that
capsazepine presents species- and modality-specific activity
on TRPV1 and also inhibits acetylcholine receptors, voltage-
gated calcium channels, and hyperpolarization-activated
cyclic nucleotide-gated channels, in addition to TRPV1 [35–
38]. However, it is important to highlight that capsazepine
was administered in this study, as described by Fernandes
and collaborators [9] who showed that repeated treatment
with this drug in vivo produces a similar profile to that
of TRPV1 KO mice in response to bacterial infection [9].
Herein, we inducedmalaria by injecting P. bergheiANKA in a
susceptible strain ofmice known to develop cerebral malaria-
like symptoms and to present with 60–100%mortality within
the secondweek following injection (for review see [19]). Our
studies were carried out at a premortality end-point, that is, 7
days following infection. At this time point, parasitaemia had
reached 11%, in agreement with previous studies [17, 22].
Evidence suggests that the innate immune response plays
an important role during the early phase of infection, with
activated monocytes and neutrophils releasing nonspecific
inflammatory mediators such as ROS and cytokines [2, 39]
and exerting their roles as phagocytes and antigen-presenting
cells when in contact with circulating infected RBCs [40].
Indeed, phagocytosis of infected RBCs by peripheral blood
and tissue phagocytes is suggested to be themajormechanism
of Plasmodium removal [41]. As a result of this interaction,
phagocytes may damage the endothelium, thus contributing
to the collapse of the circulation and in the case of cerebral
malaria, damaging the brainmicrovasculature [4, 42].During
infection, monocytes differentiate into macrophages in the
spleen and also in the brain, becoming available in the brain
microvasculature [4]. Activated macrophages contribute to
pathogen clearance and activation of lymphocytes, in an
attempt to stimulate the generation of an acquired immune
response capable of improving parasite removal and fighting
a secondary infection [2, 43].
As previously mentioned, TRPV1 can be found on
immune cells. It is then expected that antagonism of TRPV1
channels expressed on these cells would affect their pheno-
types. Our results show that at 7 days after infection, there
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Figure 4: Effect of capsazepine on peripheral blood CD3−NK1.1+ and CD3+NK1.1+ cells. (a) Representative two-colour dot-plots for
peripheral blood CD3−NK1.1+ (NK) and CD3+NK1.1+ (NKT) cell populations from uninfected and Plasmodium bergheiANKA-infectedmice
(105 infectedRBCs/animal; i.p.). Circulating (b)CD3−NK1.1+ and (c) CD3−NK1.1+cell numbers in uninfected andPlasmodiumbergheiANKA-
infected mice (105 infected RBCs/animal; i.p.). Expression of CD69 on circulating (d) CD3−NK1.1+ and (e) CD3−NK1.1+cells. Capsazepine
(50 𝜇g/animal, 2x day, for 6 days) was administered from 24 h after infection. Vehicle- (10% DMSO in saline) treated animals were used as
controls. Data are expressed as mean ± SD, 𝑛 = 5 per group. ∗𝑃 < 0.05 compared with respective uninfected (control) groups.
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Figure 5: Effect of capsazepine on spleen CD3−NK1.1+ andCD3+NK1.1+ cells. (a) Representative two-colour dot-plots for spleen CD3−NK1.1+
(NK) and CD3+NK1.1+ (NKT) cell populations from uninfected and Plasmodium berghei ANKA-infected mice (105 infected RBCs/animal;
i.p.). Spleen (b) CD3−NK1.1+ and (c) CD3−NK1.1+ cell numbers in uninfected and Plasmodium berghei ANKA-infected mice (105 infected
RBCs/animal; i.p.). Expression of CD69 on circulating (d) CD3−NK1.1+ and (e) CD3−NK1.1+ cells. Capsazepine (50𝜇g/animal, 2x day, for 6
days) was administered from 24 h after infection. Vehicle- (10% DMSO in saline) treated animals were used as controls. Data are expressed
as mean ± SD, 𝑛 = 5 per group. ∗𝑃 < 0.05 compared with respective uninfected (control) groups.
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Figure 6: Effect of capsazepine on systemic lipid peroxidation and cytokine release. (a) Aldehyde; (b) TNF𝛼 and (c) IFN𝛾 levels in plasma
samples obtained fromuninfected andPlasmodiumbergheiANKA-infectedmice (105 infectedRBCs/animal; i.p.). Capsazepine (50𝜇g/animal,
2x day, for 6 days) was administered from 24 h after infection. Vehicle- (10% DMSO in saline) treated animals were used as controls. Data are
expressed as mean ± SD, 𝑛 = 5–8 per group. #𝑃 < 0.05 compared with vehicle-treated infected group.
is activation of both monocytes and spleen macrophages
(F4/80+). Interestingly, we detected a group of circulating
F4/80+Ly6G+ cells which became markedly expanded and
activated (as denoted by IAb expression) following infection.
This is the first report to our knowledge of their contribution
to malaria. However, it was recently suggested in a model of
infection caused by vaccinia virus inoculation in C57BL/6
mice that F4/80+Ly6G+ cells are indeed monocytes with a
great capacity of producing ROS and IFN𝛾 whilst Ly6G−
monocytes produce NO and TNF𝛼 [44]. In addition, the
same study suggested that F4/80+Ly6G+ cells replace Ly6G−
monocytes as infection progresses. Herein, we show the
existence of F4/80+Ly6G+ cells also in the spleen and that
they exhibit a similar profile (in terms of number and
activation pattern) to that of Ly6G− cells in this tissue. As the
population of F4/80+Ly6G+ cells rises, GR1+ cells (myeloid-
derived suppressor cells) decline with infection. This is
expected as an increase ofmaturemonocytes and neutrophils
normally occurs as a result of infection [45, 46]. However,
at 7 days after infection, these changes in the balance and/or
activation of F4/80+, F4/80+Ly6G+, and GR1+ cells could not
be noticed at spleen level. However, it is possible that these
alterations may occur in this organ at a different time point
not addressed by this study.
Repeated treatment with capsazepine caused inhibition
of activation of both F4/80+ and F4/80+Ly6G+ cells as well
as reduction of the number of circulating F4/80+Ly6G+
cells in infected mice. Interestingly, GR1+ cell number is
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markedly increased in the same group of animals, suggesting
that, as capsazepine shuts down F4/80+- and F4/80+Ly6G+-
mediated responses, either by deactivating them or decreas-
ing their availability in the circulation, these cells are pro-
gressively replaced by GR1+ cells in order to restore the
immune responses that may be dependent on F4/80+- and
F4/80+Ly6G+monocytes. Indeed, GR1+ cells are suggested to
be recruited in order to compensate “the loss” of monocytes
that undergo polarization following Plasmodium or bacterial
infection [47, 48]. These cells are also called regulatory
monocytes/macrophages andhave a potent ability to suppress
T cell proliferation and Th1 responses [49]. On the other
hand, the definite role of these cells in critical illness is still
of debate (for review see [47]).
To evaluate the impact this shift on monocyte profile had
on inflammatory mediator release, we measured the levels
of plasma aldehydes (index of lipid peroxidation secondary
to oxidative stress) and cytokines such as TNF𝛼 and IFN𝛾.
Indeed, high systemic levels of inflammatory mediators
such as TNF𝛼, IFN𝛾, and aldehydes are correlated with
severe malaria in humans [50]. In fact, lipid peroxidation
is produced during malaria as a result of the interactions
between monocytes/macrophages and infected erythrocytes,
and also the endothelium [51, 52]. In addition, cytokines are
also released in response to malaria, triggering suppression
of erythropoiesis and activation of a variety of circulating
and spleen cells [2, 53, 54]. We found that whilst diminished
levels of lipid peroxidation-derived aldehydes and TNF𝛼
were detected in animals with malaria that had been treated
with capsazepine, IFN𝛾 production remained similar to that
observed for samples obtained from vehicle-infected mice. A
reduction of oxidative stress was expected as capsazepine was
previously suggested to inhibit oxidative stress in cultured
RAW264 monocytes/macrophages in a TRPV1 independent
manner, although this data was obtained from cells that had
not been challenged with any pathogen product [55]. Later,
TRPV1 deletion was shown to decrease ROS production
by macrophages in sepsis [9] and to modulate the release
of these mediators in other inflammatory conditions [14,
56]. However, loss of TRPV1 function has been associated
with increased production of TNF𝛼 upon bacterial infection
[7, 9, 32]. It is possible that TRPV1 differently modulates
monocytes and macrophages with respect to their ability to
produce TNF𝛼. Also, TRPV1 effects on TNF𝛼 production
may vary at different stages of malaria.
NK and NKT cells are important effectors of the innate
immune response to malaria, directly recognizing Plasmod-
ium-infected RBCs and malarial antigens, in addition to
producing IFN𝛾 in order to contain parasitaemia [2, 18, 40].
Indeed, these cells rise early during malaria and have been
suggested tomediate the differentiation ofTh1/Th2 responses
and to be essential for the trafficking of leukocytes to the brain
in cerebral malaria (for review see [2]). In addition, similarly
to macrophages, they can accumulate into the brain during
cerebral malaria, contributing to a worse outcome [18]. NK
cells have also been linked to dendritic cell maturation and T
cell activation in the spleen by releasing of cytokines [53, 57].
Also, evidence has shown that during malaria, NK cells may
undergo an intense turnover or evenmigrate out of the spleen
[18]. This was investigated at a similar time-point to that
used in our study (1 week following infection). Here, we
assessed the dynamics between circulating and spleen NK
and NKT cells. We found that P. berghei ANKA-induced
infection caused expansion of spleen NKT but not NK cell
population. This was not accompanied by any change on
circulating NK and NKT cell numbers. It is possible that at
this time-point, NK and NKT cells have already migrated to
the brain. Indeed, Hansen and collaborators showed that NK
cells accumulate into the brain of C57BL/6 mice as early as
4 days following infection with P. berghei ANKA, triggering
themigration of T cells to the brainmicrovasculature [18]. On
the other hand, we show that both NK and NKT cells became
activated in response to infection, with NK cells representing
the majority of activated cells. Disappointingly, expansion of
spleen NKT cells did not translate in their activation as only
few of these cells expressed CD69. Capsazepine treatment in
infectedmice led to a further expansion of the circulating NK
population, but its activation was similar to that of vehicle-
infected group. In addition, capsazepine treatment reduced
by half the activation of spleen NKT cells when compared to
its infected-control. We would expect that the reduction of
activation of spleen NKT cells and F4/80+Ly6G+ monocytes
by capsazepine would impair IFN𝛾 release. However, we
show capsazepine inhibitory effects on these populations do
not affect IFN𝛾 production in malaria, indicating that either
TRPV1 may not play a role on IFN𝛾 production or NK cells
become the sole source of IFN𝛾 once TRPV1 is blocked. In
addition, the lack of effect of capsazepine on parasitaemia
may be related to the similar levels of IFN𝛾 detected in both
groups of animals.
Our study provides the first evidence that TRPV1 modu-
lates malaria by mediating innate immune response, specifi-
cally by interferingwith the expansion and activation of effec-
tor cells, especiallymonocytes.We also show that TRPV1 reg-
ulates the immunological balance between different mono-
cyte populations in addition to modulating mediator release
by them. It is possible that blocking TRPV1 may be either
beneficial, as a reduction of oxidative stress may reflect on
reduced vascular dysfunction, or deleterious, as impairment
of innate response may lead to an inefficient removal of
the parasite in addition to an inefficient acquired immune
response tomalaria. However, the impact TRPV1 antagonism
may have on severe malaria outcome is of importance and
remains to be investigated.
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